⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25050720 | 0.86 | — | — | |
| SCHEMBL28810976 | 0.82 | KDM4E (0.67) | — | |
| SCHEMBL11757886 | 0.82 | KDM4E (0.67) | — | |
| SCHEMBL11631502 | 0.79 | MAPT (0.46) | — | |
| SCHEMBL21680824 | 0.79 | — | — | |
| SCHEMBL11022965 | 0.79 | TSHR (0.69) | — | |
| SCHEMBL6021690 | 0.79 | EPHX1 (0.39) | — | |
| SCHEMBL491407 | 0.78 | MAPT (0.38) | — | |
| SCHEMBL462879 | 0.77 | — | — | |
| SCHEMBL293766 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0127827-B1 | PROCESS FOR PREPARING CHLOROPYRIMIDINES | BAYER AG (DE) | 1990-01-24 | — | — | EP | claimed |
| EP-0127827-A2 | Process for preparing chloropyrimidines | BAYER AG (DE) | 1984-12-12 | — | — | EP | claimed |
| EP-3099304-B1 | CHROMAN DERIVATIVES AND THEIR USE IN THE TREATMENT OF GLAUCOMA | MAYO FOUND MEDICAL EDUCATION & RES (US) | 2024-07-17 | — | — | EP | disclosed |
| EP-4215530-A1 | ISOXAZOLINE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS | FMC Corporation (US) | 2023-07-26 | — | — | EP | disclosed |
| CN-115666538-A | FEM1B protein binding agents and uses thereof | 加利福尼亚大学董事会 | 2023-01-31 | — | — | CN | disclosed |
| EP-3795568-A1 | FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | Pharmakea, Inc. (US) | 2021-03-24 | — | — | EP | disclosed |
| CN-109286041-B | Electrolyte and secondary lithium battery | 宁德时代新能源科技股份有限公司 | 2020-12-11 | — | — | CN | disclosed |
| EP-3265456-B1 | FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA INC (US) | 2020-11-18 | — | — | EP | disclosed |
| WO-2020018610-A1 | ISOXAZOLINE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS | FMC CORPORATION (US) | 2020-01-23 | — | — | WO | disclosed |
| US-20170360794-A1 | JAK INHIBITOR | Wuxi Fortune Pharmaceutical Co., Ltd (CN) | 2017-12-21 | — | — | US | disclosed |
| EP-3248980-A1 | JAK INHIBITOR | Wuxi Fortune Pharmaceutical Co., Ltd (CN) | 2017-11-29 | — | — | EP | disclosed |
| WO-2007053776-A1 | PYRIMIDINYL-THIOPHENE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
| EP-0757682-B1 | BENZOFURAN DERIVATIVES USEFUL AS INHIBITORS OF BONE RESORPTION | FUJISAWA PHARMACEUTICAL CO (JP) | 2001-06-20 | — | — | EP | disclosed |
| US-5858995-A | ADMINISTERING TO HUMANS AND ANIMALS IN THE TREATMENT OF DISEASES CAUSED BY ABNORMAL BONE METABOLISM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-01-12 | — | — | US | disclosed |
| EP-0757682-A1 | BENZOFURAN DERIVATIVES USEFUL AS INHIBITORS OF BONE RESORPTION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-02-12 | — | — | EP | disclosed |
| WO-1995029907-A1 | BENZOFURAN DERIVATIVES USEFUL AS INHIBITORS OF BONE RESORPTION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-11-09 | — | — | WO | disclosed |
| EP-0127827-B1 | PROCESS FOR PREPARING CHLOROPYRIMIDINES | BAYER AG (DE) | 1990-01-24 | — | — | EP | disclosed |
| EP-0127827-A2 | Process for preparing chloropyrimidines | BAYER AG (DE) | 1984-12-12 | — | — | EP | disclosed |
| EP-0127827-A2 | Process for preparing chloropyrimidines | BAYER AG (DE) | 1984-12-12 | — | — | EP | disclosed |